Harvard Bioscience, Inc. Appoints Yash Singh as Executive Vice President, Cellular & Molecular Technologies
October 31, 2019 at 05:10 pm EDT
Share
Harvard Bioscience, Inc. announced that Yash Singh has been named Executive Vice President, Cellular & Molecular Technologies, reporting to Chairman, President and CEO, Jim Green. Singh will lead the newly formed Cellular and Molecular Technologies (CMT) team, which combines the former PCMI and Electro-Physiology teams into a larger scale business which leverages engineering and operations, while significantly improving sales and service coverage for the drug research and discovery market. Singh, formerly a long-tenured executive at Analogic Corporation, has more than 20 years of business strategy and operations experience with global businesses. Most recently, he served as President of Analogic’s Power and Robotic Motion Business, and prior to that role served in various executive leadership roles at Analogic. Prior to joining Analogic, Singh was a senior associate at Booz & Company.
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.
HARVARD BIOSCIENCE, INC. 
